MA40115A1 - Treatment of progressive ossifying fibrodysplasia - Google Patents
Treatment of progressive ossifying fibrodysplasiaInfo
- Publication number
- MA40115A1 MA40115A1 MA40115A MA40115A MA40115A1 MA 40115 A1 MA40115 A1 MA 40115A1 MA 40115 A MA40115 A MA 40115A MA 40115 A MA40115 A MA 40115A MA 40115 A1 MA40115 A1 MA 40115A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- acvrl
- acvr2a
- acvr2b
- antagonist
- Prior art date
Links
- 230000000750 progressive effect Effects 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 4
- 102100034111 Activin receptor type-1 Human genes 0.000 abstract 1
- 101710105225 Activin receptor type-1 Proteins 0.000 abstract 1
- 102100021886 Activin receptor type-2A Human genes 0.000 abstract 1
- 101710191686 Activin receptor type-2A Proteins 0.000 abstract 1
- 102100027647 Activin receptor type-2B Human genes 0.000 abstract 1
- 101710191689 Activin receptor type-2B Proteins 0.000 abstract 1
- 102000005606 Activins Human genes 0.000 abstract 1
- 108010059616 Activins Proteins 0.000 abstract 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 239000000488 activin Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des procédés pour le traitement de la fibrodysplasie ossifiante progressive (fop). Ces procédés consistent à administrer à un sujet souffrant d'une fop une posologie efficace d'un antagoniste du récepteur d'activine de type 2a (acvr2a) et/ou d'un antagoniste du récepteur d'activine de type 2b (acvr2b) ou d'un antagoniste du récepteur d'activine de type 1 (acvrl). Les antagonistes comprennent des protéines de fusion d'un ou de plusieurs domaines extracellulaires (ecd) d'acvr2a, acvr2b et/ou acvrl et le domaine fc d'une chaîne lourde d'immunoglobuline, et des anticorps dirigés contre acvr2a, acvr2b, acvrl ou l'activine a.The present invention provides methods for the treatment of progressive ossifying fibrodysplasia (pf). These methods include administering to a subject suffering from fop an effective dosage of an activin receptor type 2a antagonist (acvr2a) and / or an activin receptor type 2b antagonist (acvr2b) or an activin receptor type 1 antagonist (acvrl). Antagonists include fusion proteins from one or more extracellular (ecd) domains of acvr2a, acvr2b and / or acvrl and the fc domain of an immunoglobulin heavy chain, and antibodies to acvr2a, acvr2b, acvrl or activin a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049869P | 2014-09-12 | 2014-09-12 | |
| PCT/US2015/000100 WO2016039796A2 (en) | 2014-09-12 | 2015-09-14 | Treatment of fibrodysplasia ossificans progressiva |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40115A1 true MA40115A1 (en) | 2019-10-31 |
Family
ID=58698596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40115A MA40115A1 (en) | 2014-09-12 | 2015-09-14 | Treatment of progressive ossifying fibrodysplasia |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR101856A1 (en) |
| MA (1) | MA40115A1 (en) |
-
2015
- 2015-09-14 AR ARP150102922A patent/AR101856A1/en unknown
- 2015-09-14 MA MA40115A patent/MA40115A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR101856A1 (en) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40621B1 (en) | Treatment of progressive ossifying fibrodysplasia | |
| MA44146B1 (en) | COMBINATION OF ANTI-PD-1 ANTIBODIES AND BISPECIFIC ANTI-CD20/ANTI-CD3 ANTIBODIES TO TREAT CANCER | |
| MX2023000889A (en) | Bcma antibodies and use of same to treat cancer and immunological disorders. | |
| CL2018001556A1 (en) | Bcma chimeric (car) antigen receptors. (divisional application 201701515) | |
| MA37761A1 (en) | Proteins for binding to a double receptor antagonist antigen and their uses | |
| MA44594B1 (en) | Anti-ctla-4 Antibodies and Methods of Use thereof | |
| MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
| PE20170125A1 (en) | ANTIGENIC CHEMERIC RECEPTOR (CAR) THAT INCLUDES A DOMAIN OF UNION OF ANTIGENS, WHICH IS SELECTIVELY JOINED TO THE CONSTANT REGION OF THE TCR BETA 1 (TRBC1) OR TRBC2 OF T CELLS | |
| MX2017007491A (en) | Blood brain barrier receptor antibodies and methods of use. | |
| MA40662A1 (en) | Antibodies against tigit | |
| PE20171180A1 (en) | ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE | |
| EA201101009A1 (en) | ANTAGONISTS C5aR | |
| MX386491B (en) | METHODS FOR REDUCING SERUM LEVELS OF FC-CONTAINING AGENTS USING FCRN ANTAGONISTS. | |
| JOP20200157A1 (en) | Heavy chain antibodies that bind to CD22 | |
| EA201690064A1 (en) | ANTIBODIES TO LECTIN-LIKE RECEPTOR 1 OXIDIZED LDL AND METHODS OF APPLICATION | |
| EA201791227A1 (en) | DOSING MODE OF MAdCAM ANTAGONISTS | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| MX2019013734A (en) | Inhibitors and antagonists of gpr84 for the treatment of endometriosis. | |
| WO2019032945A9 (en) | Cd40-binding agents and uses thereof | |
| MA49607B2 (en) | MONOCLONAL ANTIBODY FOR IL-5Rα | |
| MA40115A1 (en) | Treatment of progressive ossifying fibrodysplasia | |
| EA201790601A1 (en) | TREATMENT OF PROGRESSIVE ASSIFIED FIBRODISPLASIA | |
| PH12017500470A1 (en) | Treatment of fibrodysplasia ossificans progressiva | |
| EP4524563A3 (en) | Flow based assays for therapeutics | |
| EA201891851A1 (en) | ANTIBODIES AGAINST BCMA AND THEIR APPLICATION FOR THE TREATMENT OF malignant neoplasms and immunological disorders |